Chimerix (NASDAQ:CMRX) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Chimerix (NASDAQ:CMRX) in a research report issued to clients and investors on Saturday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. HC Wainwright restated a “neutral” rating and set a $8.55 price target (down from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. Wedbush restated a “neutral” rating and set a $8.55 price target (up from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, Jefferies Financial Group restated a “hold” rating and set a $8.50 price target (down from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Stock Down 0.1 %

NASDAQ CMRX opened at $8.46 on Friday. Chimerix has a twelve month low of $0.75 and a twelve month high of $8.48. The firm has a market capitalization of $760.86 million, a PE ratio of -9.00 and a beta of 0.32. The stock’s 50 day moving average is $4.84 and its 200 day moving average is $2.59.

Insider Buying and Selling at Chimerix

In other news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the completion of the transaction, the chief executive officer now owns 609,603 shares in the company, valued at $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders sold 20,760 shares of company stock worth $91,175. 13.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of CMRX. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 138,098 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Chimerix by 154.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock worth $2,846,000 after purchasing an additional 496,823 shares during the last quarter. Stoneridge Investment Partners LLC raised its stake in shares of Chimerix by 22.5% in the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 8,134 shares during the last quarter. Peapod Lane Capital LLC purchased a new position in shares of Chimerix in the fourth quarter worth $2,626,000. Finally, Valeo Financial Advisors LLC raised its stake in shares of Chimerix by 78.8% in the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock worth $509,000 after purchasing an additional 64,420 shares during the last quarter. Hedge funds and other institutional investors own 45.42% of the company’s stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.